The Texas A&M Interprofessional Pharmacogenomics PILOT Whole Genome Sequencing Cohort A Study on Adverse Drug Reactions in Patients Taking Multiple Medications

What this Trial Is About

Researchers are evaluating adverse drug reactions (ADRs) linked to polypharmacy in patients taking multiple medications. This pilot study aims to use advanced pharmacogenomic technology to understand how genetic differences affect drug responses and to optimize medication plans. The study also investigates how the liver's CYP P450 enzyme pathways handle multiple drugs and tests the feasibility of integrating genetic data, electronic health records, and clinical workflows using whole genome sequencing (WGS). Participants taking five or more medications, including over-the-counter drugs and supplements, will be studied. The research involves collecting genetic data through buccal swabs and blood samples, as well as urine samples. Data will be used to develop and improve an electronic decision support dashboard to help healthcare providers identify and adjust problematic drug regimens. The study compares genotyping tests with research-use-only WGS, though WGS results will not be shared with patients or providers. During the 180-day study, participants will undergo comprehensive history and physical exams, provide various biological samples, and have their medication responses monitored. Researchers will track pharmacogenomic profiles and related adverse drug reactions to better understand individual drug metabolism and improve personalized medication management. The goal is to enhance patient safety and treatment effectiveness in those managing multiple medications.

IPGx PILOT Whole Genome Sequencing Extension Cohort